Latest Breaking News On - Renal cell - Page 4 : comparemela.com

Exelixis (EXEL) Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab

Exelixis (EXEL) Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesClaire mcconnaugheySusan hubbardExchange commissionExelixis incPublic affairsEuropean unionAmerican cancer societyResponse evaluation criteriaSolid tumorsIpsen pharmaHypertensive crisisPlantar erythrodysesthesiaImpaired wound healingPosterior leukoencephalopathy syndromeFetal toxicity

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesClaire mcconnaugheySusan hubbardExchange commissionExelixis incPublic affairsEuropean unionAmerican cancer societyResponse evaluation criteriaSolid tumorsIpsen pharmaHypertensive crisisPlantar erythrodysesthesiaWound healingPosterior leukoencephalopathy syndromeFetal toxicity

Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

France generalUnited statesUnited kingdomDennis riedlBradley mcgregorMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanTonik choueiriAnand sharmaBradford hill clinical research centerTakeda pharmaceutical companyEuropean union

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesUnited kingdomSan franciscoIpsen pharmaBradley mcgregorSteven hildemannMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanCraig marksviceTonik choueiriAnand sharma

Cabometyx® and nivolumab shows durable survival benefits

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

United statesFrance generalSan franciscoSteven hildemannMauricio burottoIpsen euronextHead of global medical affairsBradford hill clinical research centerFrom ipsenfebAmerican societyClinical oncology genitourinary cancers symposiumExecutive vice presidentChief medical officerGlobal medical affairsGlobal patientCancers symposium